so.............ALIM will adjust the price.....less money is better than no money. It wasn't being denied based on clinical effectiveness. Not sure how this will play out in the markets.
it was as expected and just a confirmation of the NICE decision from August.
Sentiment: Strong Buy
patient organizations will not accept that uk deprives itself of a viable treatment option.